Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 11, 2011, Pages 2673-2675

  King, S Travis ^a   Usery, Justin B ^a   Holloway, Katherine ^b   Koeth, Laura ^c   Cleveland, Kerry O ^d   Gelfand, Michael S ^d  

^a METHODIST UNIVERSITY HOSPITAL   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

^c Laboratory Specialists Inc   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antimicrobial resistance; Linezolid; Vancomycin

Indexed keywords

AMPICILLIN; BACTERIAL DNA; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ABDOMINAL INFECTION; ABDOMINAL WALL CELLULITIS; ABSCESS; ABSCESS DRAINAGE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATION; BROTH DILUTION; CASE REPORT; CELLULITIS; DAPTOMYCIN NONSUSCEPTIBLE ENTEROCOCCUS FAECIUM INFECTION; DIALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; HUMAN; INFECTIOUS COMPLICATION; LETTER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; METASTATIC ABDOMINAL MALIGNANCY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; SLOW LOW EFFICIENCY DIALYSIS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES; VANCOMYCIN;

EID: 80054711463     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr343     Document Type: Letter

References (9)

1. Sader HS, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis 2009; 65: 158-62.
2. Kelesidis T, Humphries R, Uslan DZ et al Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011; 52: 228-34.
3. Silverman JA, Oliver N, Andrew T et al Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45: 1799-802.
4. Palmer KL, Daniel A, Hardy C et al Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother 2011; 55: 3345-56.
5. Enoch DA, Bygott JM, Daly ML et al Daptomycin. J Infect 2007; 55: 205-13.
6. Bubalo JS, Munar MY, Cherala G et al Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother 2009; 53: 428-34.
7. Mushatt DM, Mihm LB, Dreisbach AW et al Antibiotic dosing in slow extended daily dialysis. Clin Infect Dis 2009; 49: 433-7.
8. Kielstein JT, Eugbers C, Bode-Boeger SM et al Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis - a pharmacokinetic study. Nephrol Dial Transplant 2010; 25: 1537-41.
9. Burkhardt O, Joukhadar C, Traunmuller F et al Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother 2008; 61: 224-5.